68Ga-PSMA-11 Better than Axumin at Detecting PC Recurrence, Trial Shows

68Ga-PSMA-11 Better than Axumin at Detecting PC Recurrence, Trial Shows
Among men suspected of having prostate cancer recurrence after surgery, the radiotracer 68Ga-PSMA-11 is better at detecting the cancerous lesions and provides better agreement among experts than the standard Axumin (18F-fluciclovine) tracer, a Phase 2 trial shows. The results were presented at the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held June 22–25 in Anaheim, California. The communication was titled "68Ga-PSMA-11 PET/CT detects prostate cancer at early biochemical recurrence with superior detection rate and reader agreement when compared to 18F-Fluciclovine PET/CT in a prospective head-to-head comparative phase 3 study." Radical prostatectomy — surgery to remove the prostate and surrounding tissues — is among the most common treatment options for prostate cancer. However, up to 40% of patients see their PSA levels increase after surgery. This process, called biochemical recurrence, indicates the return of cancer. Doctors use various imagining methods to estimate the size and location of recurrent tumors before starting treatment. However, traditional techniques such as computed tomography (CT)magnetic resonance imaging (MRI), and 
Subscribe or to access all post and page content.